Michael A. Proschan

26.1k total citations · 5 hit papers
153 papers, 15.2k citations indexed

About

Michael A. Proschan is a scholar working on Statistics and Probability, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Michael A. Proschan has authored 153 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Statistics and Probability, 30 papers in Cardiology and Cardiovascular Medicine and 23 papers in Epidemiology. Recurrent topics in Michael A. Proschan's work include Statistical Methods in Clinical Trials (56 papers), Statistical Methods and Bayesian Inference (20 papers) and Statistical Methods and Inference (20 papers). Michael A. Proschan is often cited by papers focused on Statistical Methods in Clinical Trials (56 papers), Statistical Methods and Bayesian Inference (20 papers) and Statistical Methods and Inference (20 papers). Michael A. Proschan collaborates with scholars based in United States, Canada and Switzerland. Michael A. Proschan's co-authors include Michael P. Fay, Eva Obarzanek, William M. Vollmer, Laura P. Svetkey, Lawrence J. Appel, Frank M. Sacks, Thomas J. Moore, Njeri Karanja, Denise G. Simons‐Morton and David W. Harsha and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Michael A. Proschan

145 papers receiving 14.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet

2001 3.7k citations Laura P. Svetkey, William M. Vollmer et al. profile →
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

2019 993 citations Michael A. Proschan, H. Clifford Lane et al. profile →
Wilcoxon-Mann-Whitney or t-test? On assumptions for hypothesis tests and multiple interpretations of decision rules

2010 766 citations Michael A. Proschan et al. profile →
The Upper Limit of Physiologic Cardiac Hypertrophy in Highly Trained Elite Athletes

1991 708 citations Antonio Pelliccia, Antonio Spataro et al. profile →
Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals

2008 677 citations Susan Moir, Shyam Kottilil et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael A. Proschan United States	49	4.5k	3.7k	2.6k	1.8k	1.8k	153	15.2k
Dean Follmann United States	42	1.7k 0.4×	1.2k 0.3×	754 0.3×	1.1k 0.6×	1.2k 0.7×	170	10.5k
David Schoenfeld United States	95	1.8k 0.4×	2.8k 0.7×	744 0.3×	1.4k 0.8×	2.6k 1.4×	347	33.2k
Charles P. Quesenberry United States	100	2.1k 0.5×	4.1k 1.1×	715 0.3×	1.7k 0.9×	3.9k 2.1×	517	33.0k
James D. Neaton United States	77	12.8k 2.9×	2.7k 0.7×	1.9k 0.7×	4.4k 2.4×	1.8k 1.0×	232	32.3k
Lawrence Joseph Canada	66	2.4k 0.5×	1.8k 0.5×	439 0.2×	1.0k 0.5×	2.0k 1.1×	292	17.3k
A. E. Ades United Kingdom	69	2.0k 0.4×	2.1k 0.6×	392 0.2×	2.8k 1.5×	1.8k 1.0×	282	29.6k
Mitchell H. Gail United States	82	567 0.1×	2.4k 0.6×	949 0.4×	1.4k 0.8×	1.5k 0.8×	338	24.1k
Thomas A Trikalinos United States	59	1.7k 0.4×	1.9k 0.5×	1.0k 0.4×	621 0.3×	1.2k 0.6×	243	18.9k
Thomas R. Fleming United States	67	2.2k 0.5×	1.0k 0.3×	565 0.2×	2.4k 1.3×	779 0.4×	223	21.1k
Michał Abrahamowicz Canada	74	2.7k 0.6×	2.5k 0.7×	411 0.2×	481 0.3×	972 0.5×	404	21.7k

Countries citing papers authored by Michael A. Proschan

Since Specialization

Citations

This map shows the geographic impact of Michael A. Proschan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Proschan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Proschan more than expected).

Fields of papers citing papers by Michael A. Proschan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Proschan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Proschan. The network helps show where Michael A. Proschan may publish in the future.

Co-authorship network of co-authors of Michael A. Proschan

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Proschan. A scholar is included among the top collaborators of Michael A. Proschan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Proschan. Michael A. Proschan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lindsell, Christopher J., Matthew S. Shotwell, Kevin J. Anstrom, et al.. (2024). The statistical design and analysis of pandemic platform trials: Implications for the future. Journal of Clinical and Translational Science. 8(1). e155–e155.

Uschner, Diane, Oleksandr Sverdlov, Jonathan Chipman, et al.. (2024). Rejoinder. Statistics in Biopharmaceutical Research. 16(4). 425–427. 1 indexed citations

Proschan, Michael A., Martha Nason, Ana M. Ortega‐Villa, & Jing Wang. (2024). Changing interim monitoring in response to internal clinical trial data. Biometrics. 80(1).

Uschner, Diane, Oleksandr Sverdlov, Jonathan Chipman, et al.. (2023). Using Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions. Statistics in Biopharmaceutical Research. 16(4). 405–413. 10 indexed citations

Sneller, Michael C., Jana Blažková, J. Shawn Justement, et al.. (2022). Combination anti-HIV antibodies provide sustained virological suppression. Nature. 606(7913). 375–381. 100 indexed citations

Sneller, Michael C., Katherine E. Clarridge, Catherine Seamon, et al.. (2019). An open-label phase 1 clinical trial of the anti-α ₄ β ₇ monoclonal antibody vedolizumab in HIV-infected individuals. Science Translational Medicine. 11(509). 28 indexed citations

Mascio, Michele Di, Jeffrey D. Lifson, Brandon F. Keele, et al.. (2019). Evaluation of an antibody to α ₄ β ₇ in the control of SIVmac239- nef-stop infection. Science. 365(6457). 1025–1029. 20 indexed citations

Morse, Caryn G., Mary McLaughlin, Michael A. Proschan, et al.. (2015). Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. AIDS. 29(17). 2297–2302. 39 indexed citations

Petersen, Tess, Kerry Townsend, Sreetha Sidharthan, et al.. (2015). High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatology International. 10(2). 310–319. 50 indexed citations

10.

Posch, Martin & Michael A. Proschan. (2012). Unplanned adaptations before breaking the blind. Statistics in Medicine. 31(30). 4146–4153. 11 indexed citations

11.

Dinoso, Jason B., Ann Wiegand, Sarah Palmer, et al.. (2009). Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proceedings of the National Academy of Sciences. 106(23). 9403–9408. 343 indexed citations

12.

Lin, Pao‐Hwa, et al.. (2003). Estimation of energy requirements in a controlled feeding trial. American Journal of Clinical Nutrition. 77(3). 639–645. 36 indexed citations

13.

Svetkey, Laura P., David W. Harsha, William M. Vollmer, et al.. (2003). Premier: a clinical trial of comprehensive lifestyle modification for blood pressure control: rationale, design and baseline characteristics. Annals of Epidemiology. 13(6). 462–471. 113 indexed citations

14.

Hsia, Judith, Edwin L. Alderman, Joel Verter, et al.. (2002). Women's Angiographic Vitamin and Estrogen trial:. Controlled Clinical Trials. 23(6). 708–727. 20 indexed citations

15.

Spirito, Paolo, Antonio Pelliccia, Michael A. Proschan, et al.. (1994). Morphology of the “athlete's heart” assessed by echocardiography in 947 elite athletes representing 27 sports. The American Journal of Cardiology. 74(8). 802–806. 313 indexed citations

16.

McMahon, Robert P., Michael A. Proschan, Nancy L. Geller, Peter H. Stone, & George Sopko. (1994). Sample size calculation for clinical trials in which entry criteria and outcomes are counts of events. Statistics in Medicine. 13(8). 859–870. 11 indexed citations

17.

Maron, Barry J., et al.. (1994). Circadian variability in the occurrence of sudden cardiac death in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 23(6). 1405–1409. 70 indexed citations

18.

Pepine, Carl J., Nancy L. Geller, Genell L. Knatterud, et al.. (1994). The Asymptomatic Cardiac Ischemia Pilot (ACIP) study: Design of a randomized clinical trial, baseline data and implications for a long-term outcome trial. Journal of the American College of Cardiology. 24(1). 1–10. 68 indexed citations

19.

Peters, Robert W., et al.. (1993). Identification of a secondary peak in myocardial infarction onset 11 to 12 hours after awakening: The cardiac arrhythmia suppression trial (CAST) experience. Journal of the American College of Cardiology. 22(4). 998–1003. 42 indexed citations

20.

Mautner, Susanne L., Heinrich G. Klues, Gisela C. Mautner, et al.. (1993). Comparison of mitral valve dimensions in adults with valvular aortic stenosis, pure aortic regurgitation and hypertrophic cardiomyopathy. The American Journal of Cardiology. 71(11). 949–953. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact